Bamco Inc. NY Has $45.88 Million Stake in CareDx, Inc. $CDNA

Bamco Inc. NY grew its stake in shares of CareDx, Inc. (NASDAQ:CDNA) by 29.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,155,180 shares of the company’s stock after buying an additional 719,523 shares during the period. Bamco Inc. NY owned approximately 6.13% of CareDx worth $45,876,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of CDNA. Allworth Financial LP acquired a new stake in shares of CareDx in the 2nd quarter valued at approximately $40,000. State of Alaska Department of Revenue acquired a new position in CareDx during the third quarter valued at approximately $43,000. Quantbot Technologies LP bought a new stake in CareDx in the third quarter valued at approximately $89,000. RiverPark Advisors LLC acquired a new stake in CareDx in the second quarter worth $149,000. Finally, Tower Research Capital LLC TRC raised its holdings in CareDx by 120.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock worth $149,000 after purchasing an additional 4,160 shares during the period.

Insider Buying and Selling at CareDx

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total transaction of $407,964.80. Following the completion of the transaction, the chief executive officer directly owned 597,405 shares of the company’s stock, valued at $12,641,089.80. This represents a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 29,636 shares of company stock worth $625,949 over the last ninety days. 4.40% of the stock is owned by corporate insiders.

CareDx Stock Up 3.4%

Shares of NASDAQ:CDNA opened at $17.01 on Monday. The firm has a market cap of $871.25 million, a price-to-earnings ratio of -42.53 and a beta of 2.52. CareDx, Inc. has a 12 month low of $10.96 and a 12 month high of $21.49. The company’s fifty day simple moving average is $19.33 and its 200 day simple moving average is $17.27.

CareDx (NASDAQ:CDNA) last announced its earnings results on Tuesday, February 24th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.12). CareDx had a negative return on equity of 6.50% and a negative net margin of 5.65%.The company had revenue of $108.39 million during the quarter, compared to analyst estimates of $102.76 million. During the same period in the previous year, the company posted $0.18 earnings per share. CareDx’s revenue for the quarter was up 25.2% on a year-over-year basis. Research analysts expect that CareDx, Inc. will post -0.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Weiss Ratings cut shares of CareDx from a “hold (c-)” rating to a “sell (d)” rating in a research report on Friday, February 27th. Zacks Research raised CareDx from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Wells Fargo & Company lifted their target price on CareDx from $18.00 to $21.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Craig Hallum cut CareDx from a “buy” rating to a “hold” rating and set a $26.00 target price for the company. in a research note on Tuesday, January 6th. Finally, BTIG Research increased their price target on CareDx from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Three equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, CareDx has an average rating of “Hold” and a consensus price target of $27.33.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.